In this study, TACC2 status was significantly associated with recurrence and worse prognosis of female breast cancer cases, and a similar tendency was also shown in the cases which received adjuvant endocrine therapy and/or chemotherapy. This evidence concerns the gene TACC2 and breast carcinoma.